Morpholino Pyrimidine Derivatives Targeting mTOR and PI3K Kinases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological inhibitors for mTOR kinase and PI3K enzymes lack potency and selectivity, limiting their effectiveness in treating cancer and other diseases.
Innovation Solution
Development of morpholino pyrimidine derivatives that exhibit potent inhibitory activity against mTOR kinase and/or PI3K enzymes, specifically targeting Class Ia and Ib enzymes, to disrupt key signaling pathways involved in cell proliferation and survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological inhibitors are used for mTOR kinase and PI3K enzymes, then treatment can be provided, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (R1-R19) at different positions of the pyrimidine core structure. Each substituent can be independently selected from specific chemical groups to optimize binding affinity for the kinase active site while maintaining selectivity against off-target enzymes, thereby simultaneously improving potency and selectivity
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, linker lengths, and molecular weight within defined ranges. This allows optimization of the inhibitor's pharmacokinetic and pharmacodynamic properties to achieve both high potency and selectivity for mTOR kinase and PI3K enzymes
2Adaptability or versatility
If morpholino pyrimidine derivatives are developed to target multiple kinases, then broader anticancer activity is achieved, but molecular complexity increases
Solution Approach 1:
The patent implements universality by designing a pyrimidine core structure that can simultaneously or sequentially target multiple kinase enzymes including mTOR kinase and various PI3K isoforms. The modular substituent system allows a single compound to exhibit broad anticancer activity across different cancer types driven by these kinases
Solution Approach 2:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a pyrimidine core, linker regions (X), and terminal substituent groups (R1-R19). This modular architecture enables systematic optimization of each segment to achieve broad kinase coverage while managing molecular complexity through structured design
Data Source
AI summary
A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.